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Abstract
Health issue: In Canada, cancers of the endometrium, ovaries, vulva, vagina, placenta and adnexa
account for 11% of all malignant neoplasms in women and 81% of all genital cancers. Although the
incidence and mortality from vulvar and vaginal cancers are very low, endometrium and ovarian
cancer are important public health problems.
Key findings: In Canada, there has been no appreciable improvement in survival for women with
advanced endometrial (EC) or ovarian cancer (OC) over the past 30 years. The prognosis of EC is
good for most patients because diagnosis is made at early stages. However, survival of OC is poor;
more than 70% of cases are diagnosed at late stages. Up to 10% of OCs is linked to familial
aggregation. Cancers of the vulva and of the vagina are very rare. The survival experience for
women with the latter is worse than for those with the former. Both share many risk factors with
cervical cancer and the recent developments in the study of HPV infection should be applicable to
these diseases as well. Of particular interest will be the advent of vaccines for the primary
prevention of HPV infection.
Data gaps and recommendations: At present, the best available means to diagnose
gynecologic malignancies is a detailed clinical examination, considering the totality of information
on potential and proven risk factors, such as age, reproductive health, sexual practices, use
unopposed estrogens or of oral contraceptives or tubal ligation, obesity, diet, smoking, and the
familial clustering of some of these cancers.
Background
In 2000, there were more than 4.7 million cases of cancer
in women worldwide, 54% of which occurred in less
developed countries. [1] Gynecologic tumours, including
cancer of the endometrium, ovary, vulva, vagina, placenta
and adnexa, accounted for 8% of all female primary
tumours worldwide and 45% of all genital cancers (cervi-
cal cancer is discussed in the chapter entitled "Cancer of
the Uterine Cervix"). In Canada, these diseases make up
11% of all neoplasias in women and 81% of all genital
cancers.
Although the incidence and mortality from endometrial
and ovarian cancer are important public health problems,
other female genital cancers are very rare. Primary
tumours of the vagina, vulva, placenta and adnexa total
0.6% of all female cancers. Neoplasia developing else-
where in the female genital tract is even less common.
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Because neoplastic disease in these sites is rare, there is
very little information on it; most of the data available are
from case series or hospital- and clinic-based studies.
Methods
Data on incidence rates and rates of mortality from gyne-
cologic cancers in Canada were obtained from Statistics
Canada and in the United States from the Surveillance,
Epidemiology, and End Results (SEER) Program. Other
epidemiologic and risk factor information was found in
published surveillance and research reports.
Results
Cancer of the Endometrium
Incidence and Mortality
Most neoplasias of the corpus of the uterus develop in the
endometrium and are endometrioid type adenocarcino-
mas. Endometrial cancer (EC) is the seventh most com-
mon malignancy affecting women worldwide, with
almost 190,000 cases annually.[2] It is the most common
uterine malignancy in Canada, accounting for 43% of all
female genital cancers. [1]
There is great variation in the incidence rates of EC inter-
nationally. The highest risk areas are Central and North
America and Polynesia, whereas rates that are 10 times
lower occur in western Africa. Figure 1 shows incidence
and mortality rates for the 10 countries with the highest
and the 10 with the lowest incidence rates, and for Canada
and the United States. Incidence rates in the latter two
countries are among the 20 highest worldwide (14.9 and
15.5 per 100,000 respectively). High-risk countries with
better resources tend to have relatively low mortality rates.
An estimated 3,500 new cases were diagnosed in Canada
in 2001, which is more than twice the number of cervical
cancer cases. [3] The age-specific incidence curves for Can-
ada and the United States are rather similar (Figure 2), the
differences in incidence being reflected somewhat propor-
tionally across all age groups. This suggests similar distri-
butions of risk factors in the female populations of the
two countries. The incidence of invasive endometrial can-
cer rises sharply after the age of 40 and begins to decline
after 75 to 79 years of age. The variation in annual inci-
dence rates among Canadian provinces is relatively small,
from 15.1/100,000 in New Brunswick to 21.5/100,000 in
Manitoba (Figure 3).
Time Trends
Figure 4 shows the trends in annual incidence and mortal-
ity rates for EC in Canada and in the United States. Rates
were steadily increasing until the mid-1970s, most likely
as a reflection of the widespread use in North America of
unopposed estrogens as hormone therapy for post-meno-
pausal symptoms. As soon as the etiologic association was
recognized, use of unopposed estrogens declined dramat-
ically, and incidence rates also began to decline. This
effect seems to have been delayed by about four years in
Canada. Since the late 1980s incidence rates have levelled
Annual age-standardized incidence and mortality rates of  invasive endometrial cancer (projection for 2000) for the 10  highest-risk and the 10 lowest-risk countries (based on inci- dence), for Canada and for the United States Figure 1
Annual age-standardized incidence and mortality 
rates of invasive endometrial cancer (projection for 
2000) for the 10 highest-risk and the 10 lowest-risk 
countries (based on incidence), for Canada and for 
the United States. Rates are per 100,000 and are stand-
ardized according to the world population of 1960. Source: 
GLOBOCAN, International Agency for Research on Cancer. 
[1]
Average (period 1994–1998) age-specific incidence rates for  invasive endometrial cancer in Canada and in the United  States Figure 2
Average (period 1994–1998) age-specific incidence 
rates for invasive endometrial cancer in Canada and 
in the United States. Incidence data for the United States 
refer to the 11 main state or metropolitan area registries 
belonging to the Surveillance, Epidemiology, and End Results 
(SEER) Program from the Cancer Surveillance Research Pro-
gram of the U.S. National Cancer Institute (NCI). Source: 
Statistics Canada, SEER database. [4]BMC Women's Health 2004, 4:S14 http://www.biomedcentral.com/1472-6874/4/S1/S14
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off or have begun to increase slightly. In general, mortality
rates have not accompanied the variations in incidence to
any important degree. They have remained low, at around
2/100,000. The trends within Canadian provinces are
similar.
Survival
The prognosis of EC is generally favourable because in
75% to 90% of cases the disease is confined to the uterus
at diagnosis, a condition that is highly curable by surgical
removal of the uterus. [5] The overall five-year survival
rate is 75%. [65] In addition to stage at diagnosis, survival
from EC is also greatly influenced by histological type and
grade of the tumour (the higher the stage, the poorer the
prognosis). The five-year survival rates are as follows: 88%
for stage I, 73% for stage II, 52% for stage III, and 27% for
stage IV. [7] Over the past 30 years there has been no
appreciable improvement in survival among women with
advanced disease. In the United States there are striking
differences in survival according to race: over the last three
decades, Black women have faced an overall survival rate
30% to 40% lower than that of white women. [6] Stage at
diagnosis, hormonal and reproductive characteristics,
socio-economic level and access to health care explain
80% of this difference. [8]
Risk Factors
EC risk is influenced by reproductive and hormonal fac-
tors. The greatest impact on the risk of endometrial cancer
comes from the exposure to estrogens without concomi-
tant intake of progesterone. Several case-control studies
have demonstrated the effects of estrogen replacement
therapy on the risk of EC. [9] In premenopausal women
sequential oral contraceptives (OCs), which were largely
used in the past, led to substantial increases in risk,
whereas modern combination OCs generally decrease risk
by approximately 50%. Maximum protection may be con-
ferred to women who receive low-dose estrogen and high-
dose progestin. [10] Tamoxifen, a non-steroidal drug with
both estrogen and anti-estrogen effects, used largely to
treat breast cancer and to prevent the occurrence of a sec-
ond breast cancer, improves survival and reduces the risk
of second breast primaries but increases the risk of
endometrial cancers. [11]
Nulliparity, [12,13] high socio-economic status, [14] mul-
tiple births, increased maternal age at first delivery [15]
and diabetes [16] confer an increased risk of EC. Unlike
the case with many cancers, EC riskis lower among
women who smoke. [17,18] The risk factor profiles for
invasive and pre-invasive endometrial cancers have been
found to be similar. [19]
Obesity has consistently been shown to be associated with
increased risk (two to five times as great) of EC, possibly
through a combination of mechanisms. Obese women
may be more prone to an increased endogenous
production of estradiol. Increased risk may also result
from continued anovulation, causing progesterone defi-
ciency. Several studies have examined the relation
between EC and physical activity because exercise lowers
Average (period 1994–1998) annual age-standardized inci- dence and mortality rates of invasive endometrial cancer for  individual Canadian provinces, for Canada and for the United  States Figure 3
Average (period 1994–1998) annual age-standardized 
incidence and mortality rates of invasive endometrial 
cancer for individual Canadian provinces, for Canada 
and for the United States. All rates refer to numbers of 
new cases or deaths per 100,000 and are standardized 
according to the Canadian population of 1991. Source: Statis-
tics Canada and SEER database. [4]
Trends in incidence and mortality rates for invasive endome- trial cancer for Canada and for the United States in the last  30 years Figure 4
Trends in incidence and mortality rates for invasive 
endometrial cancer for Canada and for the United 
States in the last 30 years. Rates are per 100,000 and are 
standardized according to the Canadian population of 1991. 
U.S. incidence data refer to the nine main SEER registries, 
and mortality data refer to the entire U.S. population. 
Source: Statistics Canada and SEER database. [4]BMC Women's Health 2004, 4:S14 http://www.biomedcentral.com/1472-6874/4/S1/S14
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serum estrone levels. Most studies report a weak to mod-
erate protective effect, but this question is still unsettled,
since the effect does not vary with the duration and
intensity level of activity and it is difficult to determine
whether obesity, a strong risk factor, is a cause or a conse-
quence of inactivity. [16]
Diets rich in whole grains, fresh fruit and vegetables as
well as consumption of fatty fish exert a protective effect
against EC, whereas high animal fat intake seems to
increase EC risk. [16,20,21] A recent Canadian study
found a reduced risk of EC with high consumption of veg-
etables, fibre, vitamin E and alcohol. [22]
Screening Strategies
Women receiving unopposed estrogens should undergo
endometrial sampling biennially (risk increases only after
two years of estrogen use), particularly if endometrial
hyperstimulation has previously been documented and
has not been treated by short-term administration of pro-
gestins. At present, there are no guidelines for the surveil-
lance of women using tamoxifen, and in particular those
taking tamoxifen who have used estrogen replacement
therapy in the past. Because these women may be at
increased risk of endometrial cancer, information on
abnormal bleeding should be obtained on a routine basis;
decisions on additional tests should be taken by their
gynecologists. Use of newer estrogen antagonists, such as
raloxifene, which seem to provide similar preventive
effects for breast cancer and none of the risk effects for
endometrial cancer, are likely to change this perception.
[23]
Women at high risk who request an endometrial evalua-
tion may undergo an office-based investigative procedure
to rule out pathology. [24] An endometrial evaluation
should also be performed in women with a history of
Lynch II syndrome, a condition associated with a very
high risk of endometrial carcinoma.[25]
High-risk women should be evaluated by any of the fol-
lowing detection tests: (i) cervico-vaginal cytology, (ii)
endometrial cytology, (iii) endometrial biopsy, (iv)
dilatation and curettage, (v) transvaginal ultrasonogra-
phy, (vi) magnetic resonance imaging or computerized
tomography, or (vii) hysteroscopy.
The only group of women for whom there are explicit
guidelines for screening are those with a positive test or
positive family history of hereditary non-polyposis colon
cancer. The American Cancer Society recommends annual
screening beginning at age 35. [26]
Routine screening of asymptomatic women using any of
the techniques noted has not been proven to be of benefit.
[27] No screening test has been assessed with respect to its
impact on mortality from endometrial cancer. The Pap
test lacks sufficient sensitivity to reliably detect endome-
trial cancer or its precursors, but it may help to reveal the
presence of endometrial cells on a smear of a post-meno-
pausal woman not taking exogenous hormones. [28,29]
One could argue that although EC is common, its attend-
ant morbidity is relatively low as compared with that of
other female neoplasms, such as breast and cervical can-
cers. The high cost and discomfort to the patient of most
procedures make them unattractive as large-scale, cost-
effective screening tools.
Primary Prevention
Preventing EC through public and professional education
seems to be a sensible approach. Physician education
should include increasing awareness that EC is the most
common gynecologic malignancy and that risk can be
reduced by early intervention with endometrial biopsy
and treatment in the setting of abnormal uterine bleeding,
by administration of progestational therapy for post-men-
opausal patients on estrogen-only regimens, and by refer-
ral for endometrial biopsy of those patients who have
endometrial or atypical glandular cells on Pap smear.
Public education concerning the risks of endometrial can-
cer should include awareness of (i) the need to maintain
a proper weight, (ii) the risks associated with unopposed
estrogen therapy, (iii) the value of OC use in reducing risk,
and (iv) the most common signs and symptoms of the
disease. [24]
Cancer of the Ovary
Incidence and Mortality
Accounting for 3% of all cancers in women and figureing
more than 165,000 new cases estimated in2001, ovarian
cancer is the sixth most frequent female cancer and the
sixth leading cause of death in women worldwide. [2] In
Canada, where ovarian cancer accounts for 4% of all
female cancers or 31%ofall genital cancers in women, it is
estimated that in 2001 there were 2,500 new cases and
1,500 deaths.[3]
There is substantial variation in incidence rates of ovarian
cancer internationally, from 3/100,000 in central Africa to
13/100,000 in northern Europe. Developing nations have
incidence rates that are approximately half those of the
most resource-rich countries. Canada and the United
States are among the countries with the highest rates of
ovarian cancer worldwide, with rates of 12 and 11 per
100,000 respectively [1] (Figure 5). Within countries,
mortality rates are generally not good indicators of the
region's incidence, and unlike the situation for other
gynecologic cancers, mortality from ovarian cancer doesBMC Women's Health 2004, 4:S14 http://www.biomedcentral.com/1472-6874/4/S1/S14
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not seem to be related to the country's level of
development.
The incidence of ovarian cancer rises sharply after the age
of 40 and peaks in the eighth decade of life [3,4] (Figure
6). In Canada, 63% of cases are diagnosed after the age of
50. [30] Canadian incidence and mortality rates show lit-
tle variation. The lowest age-standardized incidence rate is
10/100,000 in Prince Edward Island, and the highest is
13.7/100,000 in Quebec [31] (Figure 7).
Figure 8 shows time trends in the incidence and mortality
of ovarian cancer in Canada and in the United States for
the past 30 years. The rates in Canada have been fairly sta-
ble in the past 15 years. In the United States the marked
and abrupt increase in incidence in the late 1980s
probably reflects more active case finding. Mortality rates
in Canada have declined slowly over the past 30 years but
Annual age-standardized incidence and mortality rates of  invasive ovarian cancer (projection for 2000) for the 10 high- est-risk and the 10 lowest-risk countries (based on inci- dence), for Canada and for the United States Figure 5
Annual age-standardized incidence and mortality 
rates of invasive ovarian cancer (projection for 2000) 
for the 10 highest-risk and the 10 lowest-risk coun-
tries (based on incidence), for Canada and for the 
United States. Rates are per 100,000 and are standardized 
according to the world population of 1960. Source: GLOBO-
CAN, International Agency for Research on Cancer. [1]
Average (period 1994–1998) age-specific incidence rates for  invasive ovarian cancer in Canada and in the United States Figure 6
Average (period 1994–1998) age-specific incidence 
rates for invasive ovarian cancer in Canada and in the 
United States. U.S. incidence data refer to the 11 main 
SEER registries. Source : Statistics Canada, SEER database. [4]
Average (period 1994–98) annual age-standardized incidence  and mortality rates of invasive ovarian cancer for individual  Canadian provinces, for Canada and for the United States Figure 7
Average (period 1994–98) annual age-standardized 
incidence and mortality rates of invasive ovarian can-
cer for individual Canadian provinces, for Canada and 
for the United States. All rates refer to numbers of new 
cases or deaths per 100,000 and are standardized according 
to the Canadian population of 1991. Source: Statistics Can-
ada and SEER database. [4]
Trends in incidence and mortality rates for invasive ovarian  cancer for Canada and for the United States in the last 30  years Figure 8
Trends in incidence and mortality rates for invasive 
ovarian cancer for Canada and for the United States 
in the last 30 years. Rates are per 100,000 and are stand-
ardized according to the Canadian population of 1991. U.S. 
incidence data refer to the nine main SEER registries, and 
mortality data refers to the entire U.S. population. Source: 
Statistics Canada and SEER database. [4]BMC Women's Health 2004, 4:S14 http://www.biomedcentral.com/1472-6874/4/S1/S14
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seem to have levelled off in recent years. Substantial
reductions in incidence between 1969 and 1998 were
reported in British Columbia, Manitoba and Quebec
(data not shown).
Most ovarian cancers are epithelial in origin, but there are
many different histological presentations of the tumour.
Nonetheless, there seems to be evidence for the existence
of precancerous lesions, [32] although these are difficult
to study because of their location and because the disease
is usually detected only in advanced stages, only 25%
being diagnosed while still localized. [30]
Survival
Ovarian cancer tends to be a fatal disease because it is usu-
ally not detected before extensive intraperitoneal spread.
The most important factor in predicting survival from
ovarian cancer is stage at diagnosis. [33] Since 70% of
patients present with stage III or IV at diagnosis, the five-
year survival rate for all stages of ovarian cancer is less
than 40%, although women with stage I disease have five-
year survival rates between 80% and 90%. [34] Women
with disease confined to the ovaries are four times more
likely to survive for five years than women who have a
diagnosis of distant metastatic disease.
Risk Factors
Of all ovarian cancers, 5% to 10% are hereditary, and
most of these (65% to 75%) belong to the hereditary
breast-ovarian cancer syndrome group that is linked to
mutations in BRCA1 or BRCA2 tumour suppressor genes.
[30,35] The median age at diagnosis of familial ovarian
cancer is considerably lower, at approximately 59 years,
than that for sporadic cancers. [36]
Some reproductive factors result in significant protection
against ovarian cancer: OC use reduces the risk by 30% to
40% and so does a term pregnancy (40%). [10,37,38]
Tubal ligation has been associated with a reduction in risk
of 60% and hysterectomy with 30%. [37]. Both OC use
and tubal ligation have also shown substantial protection
against ovarian cancer in BRCA1 and BRCA2 mutation
carriers. [39,40]
Several other risk factors (e.g. diet, alcohol) that have been
studied have not shown consistent effects.
Screening Strategies
Several factors render screening for ovarian cancer imprac-
tical: there is no defined precursor lesion as the target,
there are many possible etiologic pathways, access to the
ovaries is difficult, and most ovarian pathologies that pro-
duce an abdominal mass are not malignant.
Tumour markers, of which the CA 125 test is the most
promising, have been the focus of considerable attention.
The U.S. NCI-PDQ® program has evaluated the CA 125
test, transvaginal ultrasound, and pelvic examination and
has concluded that there is insufficient evidence to recom-
mend any of these methods. Similar conclusions were
reached by the U.S. Preventive Services Task Force and by
the Canadian Task Force on Preventive Health Care. [41]
Large randomized trials are currently under way that use a
multi-modal approach testing for the serum tumour
marker CA 125 followed by transvaginal ultrasound, but
preliminary results are still conflicting. Additional data are
needed to fully evaluate the impact of screening on
morbidity, mortality, health economics and psychosocial
issues. [42]
Primary Prevention
OC use, tubal ligation and prophylactic oophorectomy
have been suggested as possible manoeuvres to prevent
ovarian cancer in women who have a strong family his-
tory or have been found to be positive for a BRCA muta-
tion. However, none of these approaches has been shown
to reduce the mortality from ovarian cancer or the inci-
dence of advanced disease.
Cancer of the Vulva
Incidence and Mortality
Although tumours in the vulva occur two to three times as
frequently as those in the vagina, they are still a rare find-
ing. The cancer registry reporting the most elevated
incidence rate of vulvar cancer is that of Prince Edward
Island in Canada (2.6/100,000 women). Rates above 2/
100,000 are found elsewhere, in Peru and Brazil (2.5/
100,000 and 2.3/100,000 respectively). [43] All provinces
in Canada have rates above 1/100,000 women; these are
among the highest reported worldwide.
Survival
The overall survival rate of vulvar cancer is 46%. [44] The
main prognostic feature in cancer of the vulva is lymph
node involvement. Stage I disease has a five-year survival
rate ranging from 90% to 94%, stage II from 81% to 91%,
stage III from 36% to 74%, and stage IV from 19% to 31%.
[45]
Risk Factors
There seem to be two distinct risk factor profiles for vulvar
cancer that are age-dependent. Cancers developing in
younger women (< 65 years) tend to have the same risk
profile as other anogenital cancers, i.e. association with
low socio-economic status, high-risk sexual behaviours,
and the presence of human papillomavirus (HPV) infec-
tion and smoking. [46-48] In addition, these neoplasms
occur more frequently in women with a diagnosis of other
cancers, particularly those related to HIV infection andBMC Women's Health 2004, 4:S14 http://www.biomedcentral.com/1472-6874/4/S1/S14
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cigarette smoking. [47] Risk of vulvar cancer and of its pre-
cursor, vulvar intraepithelial neoplasia (VIN), is
substantially greater among immunocompromised
women; in fact, 1% to 37% of HIV-positive women also
have VIN. [48]
Women with late-onset vulvar cancers (55 to 85 years) are
typically without a previous history of sexually transmit-
ted infections and tend not to be smokers. HPV DNA is
found in only 15% of these cancers. [47]
It is not yet well understood whether the trend of increas-
ing rates of vulvar neoplasia is due to greater public and
physician awareness about the risk of HPV-associated dis-
eases or whether it is a cohort effect associated with
changes in sexual practices that began in the late 1960s,
such as increased sexual activity and increased prevalence
of smoking among women of reproductive age.
Prevention
Because there is evidence of diagnostic delays, that is,
women seek medical care in advanced stages of the dis-
ease, some authors recommend that women perform self-
examination monthly and also that physicians be made
aware of the features of this disease. [48] Given that
smoking is an important risk factor of vulvar as well as of
other primary anogenital cancers, patients who smoke
should be advised and encouraged to quit. [49] Women
with HIV infection should be monitored for anogenital
lesions in the vulva, vagina and cervix.
Cancer of the Vagina
Incidence and Mortality
Neoplasms of the vagina are extremely rare. The reported
annual age-standardized incidence rate (ASIR) is fewer
than 1/100,000 women in all countries with the exception
of Argentina (1.5/100,000) and Colombia (1.2/100,000).
[43] Nova Scotia is the Canadian province with the high-
est ASIR for vaginal cancers, at 0.8/100,000, ranked fourth
highest in the world. For the other reporting provinces,
rates vary between 0.3/100,000 and 0.7/100,000. Since
neoplasia found in the vagina may represent metastasis or
infiltration of primary cancers occurring elsewhere in the
body, it is possible that such rates are inflated.
Survival
The survival of patients with vaginal cancers is generally
poor: stage I disease has a five-year survival rate of 64% to
90%, stage II of 29% to 66%, and stages III and IV of 0%
to 40%. [44]
Risk Factors
Most vaginal cancers are squamous. Clear cell adenocarci-
nomas used to occur in young women as a consequence
of maternal exposure to diethylstilbestrol (DES) before
the 12th week of gestation. [50] Other risk factors include
hysterectomy, endometriosis, and frequent vaginitis due
to chronic irritation. [50,51] More recently, an association
between exposure to DES and increased risk of squamous
neoplasia of the cervix and the vagina was found in long-
term follow-up of two large cohorts of exposed women
who were compared with unexposed controls. [52]
A recent population-based study found that HPV infec-
tion, lifetime number of sexual partners, early age at first
intercourse, and smoking were associated with an
increased risk of in situ and invasive vaginalneopla-
sia.[53] In addition, a higher risk was associated with a
history of other anogenital cancers and previous hysterec-
tomy (in the absence of previous anogenital cancer).[53]
HPV DNA is found in themajority of vaginal tumours,
pointing to a role for the virus in the etiology of vaginal
cancers, as has been demonstrated for cervical can-
cer.[53,54] Because most women infected with HPV do
not developcancer, it is possible that genetic susceptibility
plays an important part. Daling et al.[53] found that
women with a first-degree relative with anogenital cancer
had almost three times the risk of vaginal cancer.
Prevention
Because cancer in the vagina may appear in association
with other anogenital cancers, the follow-up of women
with a diagnosis of these other cancers should include
routine cytological screening and colposcopic examina-
tion of the vagina. The health care provider should keep
in mind that this procedure should be performed even if
the patient has had a hysterectomy.
Smoking cessation should be advised, since smoking is a
risk factor for cancer of the vagina as well as for neoplasms
of other anogenital sites. In addition, the risk of a second
cancer for women with cancer of the vagina and of the
vulva is greater than that expected according to the inci-
dence rate of these cancers. A study using data from the
U.S. SEER program found that most of the excess second
cancers were related to smoking (lung, esophagus and
upper respiratory tract) or to HPV infection (cervix, vulva,
vagina and anus). [49]
Discussion
Data Limitations
Although there is a relative wealth of information on the
factors that may cause women to be at higher risk of any
of these gynecologic cancers, data on the efficacy of vari-
ous screening strategies are still incomplete
Recommendations
Modifiable risk factors such as exposure to unopposed
estrogens, obesity and diet play an important role in
increasing the risk of endometrial cancer. Therefore,BMC Women's Health 2004, 4:S14 http://www.biomedcentral.com/1472-6874/4/S1/S14
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public and professional education to prevent this disease
should be encouraged and improved. Concerning risk
factors, there is good evidence for a protective role of oral
contraceptives, which should be taken into consideration
by practitioners when judging risks of familial ovarian
cancer.
Although several screening methods have been studied,
including several tumour markers, none has been found
yet to be particularly useful in reducing the incidence of
advanced disease or mortality from ovarian cancer; thus
further research is needed to develop diagnostic methods
capable of diagnosing disease at an early stage. At present,
the best available means of diagnosing gynecologic malig-
nancies is through a detailed clinical examination as part
of routine health care, provided that the physician
considers the totality of information on potential and
proven risk factors, such as age, reproductive health, sex-
ual practices, smoking and the familial clustering of some
of these cancers.
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